Baxdrostat
CinCor Pharma
['cardio']
#brightn - phase 2 trial of #baxdrostat for treatment-resistant hypertension this aldosterone synthase inhibitor, baxdrostat led to substantial reductions in sbp and dbp in patients with tx-resistant #hypertension #aha22 #cardiotwitter 
Cardiologist FACC, FESC | Physician-scientist @UVMHealth | Nature Lover?? | #HeartFailure???????| #HFA & #EACVI Committee @escardio | Content Catalyst in @TCTMD